Do newer IQOS devices change how people puff? study investigates
NCT ID NCT07712887
First seen Jul 20, 2026 · Last updated Jul 31, 2026 · Updated 3 times
Summary
This study compares how people use two generations of IQOS heated tobacco devices—the newer IQOS Iluma i and the older IQOS 2.4—and how each affects their smoking behavior and sensory experience. Participants attend two lab visits, use both devices, and have their puffing patterns recorded. The goal is to see if device design or tobacco stick flavor influences puffing, throat hit, and satisfaction.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- IQOS Iluma i and IQOS 2.4 heated tobacco devices
- What this could lead to
- If it works, this could help understand how newer heated tobacco devices affect user behavior and satisfaction.
- What could go wrong
- This is a small, early-stage study with only 50 participants, so results may not apply to all users. It does not test health effects or long-term outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2026
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Current IQOS user (at least 3 days per week in the past 30 days) * Age 18 to 65 years * Generally healthy * Willing to provide informed written consent * Willing to attend all laboratory visits * Willing to abstain from all nicotine and tobacco products for at least 12 hours before each visit Exclusion Criteria: * Use of any tobacco products other than IQOS in the past 30 days * Chronic cardiovascular conditions, seizures, or abnormal blood pressure * Current psychiatric disorder requiring active treatment, including major depressive disorder * Regular use of prescription medications that may influence cardiovascular function, respiratory function, or nicotine metabolism (excluding vitamins or birth control) * Use of cocaine, opioids, benzodiazepines, or methamphetamines in the past month * Marijuana use on more than 15 days per month * Current pregnancy or breastfeeding * Plans to quit nicotine or tobacco products within the next 30 days
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Nicotine dependence are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Clinical Aerosol Technology Laboratory (CATLAB), American University of Beirut
RECRUITINGBeirut, Beirut, 1107 2020, Lebanon
-
Clinical Aerosol Technology Laboratory (CATLAB), American University of Beirut
RECRUITINGBeirut, Lebanon
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A mechanistic test of treatment strategies to foster practice quitting
- Project QUIT+: adapting and testing a smoking cessation intervention for transgender and gender expansive individuals
- A new weapon against secondhand smoke: home visits that inspire change
- Text messages and clinic prompts may boost smoking cessation
- Can a short tobacco break curb cannabis cravings?
- Mindfulness meets wearable tech in a new bid to break the smoking habit